NCT03770572View on ClinicalTrials.gov

Gene Therapy for Children With CLN3 Batten Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
CLN3Batten Disease
Interventions
GENETIC

Low dose CLN-301

Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at low dose

GENETIC

High dose CLN-301

Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at high dose

Trial Locations (1)

43201

Nationwide Children's Hospital, Columbus

Sponsors
All Listed Sponsors
lead

Alcyone Therapeutics, Inc

INDUSTRY

NCT03770572 - Gene Therapy for Children With CLN3 Batten Disease | Biotech Hunter | Biotech Hunter